ELI LILLY & CO

Discover how Eli Lilly’s Q2 2024 results and GLP‑1 drugs Mounjaro & Zepbound drive record sales, superior weight loss, and a bullish market outlook.

Explore Eli Lilly’s latest moves—weight‑loss breakthroughs, KRAS‑targeted oncology, and rising institutional bets—ahead of the 5 August earnings.

How Eli Lilly’s cell‑based platform strategy drives rapid, scalable therapies across diabetes, oncology and neuro‑degeneration, blending manufacturing innovation with promising early clinical results.

See why Eli Lilly’s GLP‑1 drugs Mounjaro and Zepbound hit a new all‑time high and how the company’s share‑sale strategy fuels future growth.

Explore how Eli Lilly’s AI‑driven R&D and targeted acquisitions are reshaping its pipeline, cutting costs, and battling patent cliffs in a competitive pharma market.

Explore how Eli Lilly’s Medicare weight‑loss rollout, Centessa acquisition, and breakthrough oncology drug Jaypirca fuel a rally in defensive healthcare stocks.

Explore Eli Lilly’s dual obesity strategy: Retatrutide’s multi‑modal benefits vs. Foundayo’s oral GLP‑1 breakthrough, market‑access, patent, and M&A insights.

Discover how Eli Lilly’s new obesity drugs—retatrutide, Foundayo, and Zepbound—show Phase 3 promise for weight loss, diabetes and sleep apnea, reshaping the market.

Explore how Eli Lilly’s 50% cut to its Alzey plant and the $1.9 B partnership with Ascidian Therapeutics reshape its strategy, boost portfolio diversity, and secure long‑term growth.

Explore Eli Lilly’s latest shareholder moves, breakthrough obesity and oncology trials, and strategic bond issuance that strengthen its market position and future growth.